Kenvue Declares Quarterly Dividend of $0.2075
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 28 2026
0mins
Should l Buy KVUE?
Source: seekingalpha
- Quarterly Dividend Announcement: Kenvue has declared a quarterly dividend of $0.2075 per share, consistent with previous distributions, indicating the company's ongoing ability to maintain stable cash flow, which is expected to bolster investor confidence.
- Dividend Yield: The forward yield of 4.74% offers relative attractiveness in the current market environment, potentially drawing in investors seeking stable income amidst market volatility.
- Shareholder Record Dates: The dividend will be payable on February 25, with a record date of February 11 and an ex-dividend date also on February 11, ensuring shareholders receive timely returns and enhancing loyalty towards the company.
- Market Reaction Expectations: Despite mixed analyst opinions on the Kenvue and Kimberly-Clark merger, the stable dividend policy may alleviate some market concerns regarding financial integration post-merger.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KVUE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KVUE
Wall Street analysts forecast KVUE stock price to rise
8 Analyst Rating
1 Buy
7 Hold
0 Sell
Hold
Current: 18.550
Low
17.00
Averages
18.86
High
23.00
Current: 18.550
Low
17.00
Averages
18.86
High
23.00
About KVUE
Kenvue Inc. is a consumer health company. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kenvue to Announce Q4 Earnings on February 17
- Earnings Announcement Date: Kenvue (KVUE) is set to announce its Q4 earnings on February 17 after market close, with consensus EPS estimate at $0.22, reflecting a 15.4% year-over-year decline, and revenue estimate at $3.69 billion, down 0.3% year-over-year, indicating performance challenges ahead.
- Historical Performance: Over the past two years, Kenvue has exceeded EPS estimates 100% of the time and revenue estimates 50% of the time, although recent downward revisions in both EPS and revenue forecasts suggest a weakening market confidence in its future performance.
- Revision Trends: In the last three months, Kenvue has seen no upward revisions in EPS estimates, with five downward adjustments, while revenue estimates also faced four downward revisions without any upward changes, highlighting analysts' cautious outlook on the company's profitability.
- Market Focus: As the merger vote with Kimberly-Clark approaches, there is significant market interest in the combined financial performance of both companies, particularly regarding market share and value enhancement in the household products sector.
See More
Key Companies to Monitor This Week: PCE, Walmart, Palo Alto, Analog Devices, Deere, and Others
- Market Performance: Equities experienced a decline last week, with all three major indexes falling by at least 1.2%.
- Economic Indicators: This downturn occurred despite a better-than-expected jobs report from the Bureau of Labor Statistics and a relatively stable inflation report.
See More
AI Turbulence Impacts Market Performance
- Increased Market Volatility: Last week, stocks in software, real estate, financial services, and logistics faced selling pressure due to concerns over AI-related disruptions, with the Nasdaq Composite falling 0.2% and a weekly loss of 2.1%, indicating market sensitivity to AI impacts.
- Consumer Spending Data Focus: This week's highlight will be the Personal Consumption Expenditures (PCE) report on Friday, which will provide insights into consumer spending in December and inflation trends, especially following last week's unexpected slowdown in the Consumer Price Index (CPI).
- Corporate Earnings in Spotlight: Walmart (WMT) is set to release its fourth-quarter earnings on Thursday, marking the first report under new CEO John Furner, making it a key indicator of consumer spending that the market is eagerly anticipating.
- Ongoing AI Impact: As AI tools' potential effects intensify across various sectors, software stocks like Salesforce (CRM) and ServiceNow (NOW) have seen significant declines, reflecting the market's heightened vigilance regarding AI disruptions, necessitating close monitoring of future industry developments.
See More
Powell's Tenure Nears End, Market Focuses on His Legacy
- Monetary Policy Balance: As Fed Chair Powell's tenure approaches its end, the market is keenly focused on his performance in balancing maximum employment and stable prices, especially with the upcoming release of the latest meeting minutes, marking one of his final meetings in office.
- Interest Rate Challenges: During Powell's leadership, the Fed has navigated emergency interventions and an aggressive rate-hiking cycle, with the benchmark rate rising from near zero to over 5%; despite initially viewing inflation as 'transitory,' achieving a 'soft landing' for the economy will be a key part of his legacy.
- Market Reaction Expectations: Investors are optimistic about the upcoming personal consumption expenditure data, although the cooler-than-expected CPI could impact the Fed's interest rate outlook, with markets currently pricing in only two quarter-point cuts for the year.
- Industry Dynamics Observation: As concerns over AI disruption grow, stocks in software, finance, and real estate have seen declines, prompting investors to search for the next potentially affected sectors, with Walmart and Deere's upcoming earnings reports likely to be focal points for market attention.
See More
Kenvue Acquisition Progress Significant Amid Stock Fluctuations
- Acquisition Progress: Kenvue's acquisition proposal with Kimberly-Clark received overwhelming support from approximately 99% of shareholders, with the transaction expected to close in the second half of 2026, marking a significant step towards creating a global health and wellness leader and enhancing market competitiveness.
- Stock Fluctuations: Kenvue shares fell 0.32% to $18.48 during Thursday's premarket trading, reflecting short-term strength despite an 11.55% decline over the past 12 months, indicating market uncertainty.
- Financial Outlook: Kenvue is set to report earnings on February 17, 2026, with an estimated EPS of 22 cents and revenue of $3.70 billion, showing revenue growth but a decline in EPS from the previous year, highlighting profitability pressures.
- Analyst Ratings: The stock currently holds a Hold rating with an average price target of $20.18, and recent downgrades from Jefferies and Canaccord Genuity indicate a cautious market outlook regarding its future performance.
See More
Kenvue to Announce Q4 and Full Year 2025 Financial Results
- Earnings Announcement Schedule: Kenvue Inc. will release its Q4 and full year 2025 financial results after market close on February 17, 2026, demonstrating the company's commitment to transparency.
- No Conference Call: Due to the pending transaction with Kimberly-Clark, Kenvue will not host a quarterly conference call to review its financial results, which may affect investors' immediate understanding of the company's financial health.
- Company Background: Kenvue Inc. is the world's largest pure-play consumer health company by revenue, featuring iconic brands such as Aveeno®, BAND-AID®, Johnson’s®, Listerine®, Neutrogena®, and Tylenol®, showcasing its leadership in the consumer health sector.
- Brand Influence: Kenvue's brands are science-backed and recommended by healthcare professionals globally, indicating a high level of trust and influence in the market, further solidifying its competitive position.
See More
Kenvue to Announce Q4 Earnings on February 17
- Earnings Announcement Date: Kenvue (KVUE) is set to announce its Q4 earnings on February 17 after market close, with consensus EPS estimate at $0.22, reflecting a 15.4% year-over-year decline, and revenue estimate at $3.69 billion, down 0.3% year-over-year, indicating performance challenges ahead.
- Historical Performance: Over the past two years, Kenvue has exceeded EPS estimates 100% of the time and revenue estimates 50% of the time, although recent downward revisions in both EPS and revenue forecasts suggest a weakening market confidence in its future performance.
- Revision Trends: In the last three months, Kenvue has seen no upward revisions in EPS estimates, with five downward adjustments, while revenue estimates also faced four downward revisions without any upward changes, highlighting analysts' cautious outlook on the company's profitability.
- Market Focus: As the merger vote with Kimberly-Clark approaches, there is significant market interest in the combined financial performance of both companies, particularly regarding market share and value enhancement in the household products sector.
See More
Key Companies to Monitor This Week: PCE, Walmart, Palo Alto, Analog Devices, Deere, and Others
- Market Performance: Equities experienced a decline last week, with all three major indexes falling by at least 1.2%.
- Economic Indicators: This downturn occurred despite a better-than-expected jobs report from the Bureau of Labor Statistics and a relatively stable inflation report.
See More
AI Turbulence Impacts Market Performance
- Increased Market Volatility: Last week, stocks in software, real estate, financial services, and logistics faced selling pressure due to concerns over AI-related disruptions, with the Nasdaq Composite falling 0.2% and a weekly loss of 2.1%, indicating market sensitivity to AI impacts.
- Consumer Spending Data Focus: This week's highlight will be the Personal Consumption Expenditures (PCE) report on Friday, which will provide insights into consumer spending in December and inflation trends, especially following last week's unexpected slowdown in the Consumer Price Index (CPI).
- Corporate Earnings in Spotlight: Walmart (WMT) is set to release its fourth-quarter earnings on Thursday, marking the first report under new CEO John Furner, making it a key indicator of consumer spending that the market is eagerly anticipating.
- Ongoing AI Impact: As AI tools' potential effects intensify across various sectors, software stocks like Salesforce (CRM) and ServiceNow (NOW) have seen significant declines, reflecting the market's heightened vigilance regarding AI disruptions, necessitating close monitoring of future industry developments.
See More
Powell's Tenure Nears End, Market Focuses on His Legacy
- Monetary Policy Balance: As Fed Chair Powell's tenure approaches its end, the market is keenly focused on his performance in balancing maximum employment and stable prices, especially with the upcoming release of the latest meeting minutes, marking one of his final meetings in office.
- Interest Rate Challenges: During Powell's leadership, the Fed has navigated emergency interventions and an aggressive rate-hiking cycle, with the benchmark rate rising from near zero to over 5%; despite initially viewing inflation as 'transitory,' achieving a 'soft landing' for the economy will be a key part of his legacy.
- Market Reaction Expectations: Investors are optimistic about the upcoming personal consumption expenditure data, although the cooler-than-expected CPI could impact the Fed's interest rate outlook, with markets currently pricing in only two quarter-point cuts for the year.
- Industry Dynamics Observation: As concerns over AI disruption grow, stocks in software, finance, and real estate have seen declines, prompting investors to search for the next potentially affected sectors, with Walmart and Deere's upcoming earnings reports likely to be focal points for market attention.
See More
Kenvue Acquisition Progress Significant Amid Stock Fluctuations
- Acquisition Progress: Kenvue's acquisition proposal with Kimberly-Clark received overwhelming support from approximately 99% of shareholders, with the transaction expected to close in the second half of 2026, marking a significant step towards creating a global health and wellness leader and enhancing market competitiveness.
- Stock Fluctuations: Kenvue shares fell 0.32% to $18.48 during Thursday's premarket trading, reflecting short-term strength despite an 11.55% decline over the past 12 months, indicating market uncertainty.
- Financial Outlook: Kenvue is set to report earnings on February 17, 2026, with an estimated EPS of 22 cents and revenue of $3.70 billion, showing revenue growth but a decline in EPS from the previous year, highlighting profitability pressures.
- Analyst Ratings: The stock currently holds a Hold rating with an average price target of $20.18, and recent downgrades from Jefferies and Canaccord Genuity indicate a cautious market outlook regarding its future performance.
See More
Kenvue to Announce Q4 and Full Year 2025 Financial Results
- Earnings Announcement Schedule: Kenvue Inc. will release its Q4 and full year 2025 financial results after market close on February 17, 2026, demonstrating the company's commitment to transparency.
- No Conference Call: Due to the pending transaction with Kimberly-Clark, Kenvue will not host a quarterly conference call to review its financial results, which may affect investors' immediate understanding of the company's financial health.
- Company Background: Kenvue Inc. is the world's largest pure-play consumer health company by revenue, featuring iconic brands such as Aveeno®, BAND-AID®, Johnson’s®, Listerine®, Neutrogena®, and Tylenol®, showcasing its leadership in the consumer health sector.
- Brand Influence: Kenvue's brands are science-backed and recommended by healthcare professionals globally, indicating a high level of trust and influence in the market, further solidifying its competitive position.
See More
